Crown Bioscience Launches ‘3D Ex Vivo Patient Tissue Platform’ to Improve Predictability of Immuno-Oncology Drug Candidates

Corporate

October 8, 2021 - Crown Bioscience, a JSR Life Sciences Company, announced the launch of its 3D Ex Vivo Patient Tissue Platform’ to improve predictability of immuno-oncology drug candidates.

For more information on Crown Bioscience’s 3D Ex Vivo Patient Tissue Platform, visit Crown Bioscience's webpage on the new service.
Link to PR
https://blog.crownbio.com/press/crown-bioscience-launches-3d-ex-vivo-patient-tissue-platform